Solid Biosciences CEO Bo Cumo discusses recent DMD data for the company's microdystrophin gene therapy, and explains the development and regulatory steps ahead

Solid Biosciences' CEO, Bo Cumbo, discusses the company's gene therapy advancements for Duchenne muscular dystrophy, emphasizing their focus on improved delivery methods via the Polaris capsid. Cumbo highlights recent data from a Phase 1-2 study involving 41 patients, noting the comprehensive safety profile and consistent microdystrophin expression across various assays. The discussion covers the durability of the therapy, with positive results seen in patients followed for a year, and the potential for cardiac benefits. Cumbo also addresses the FDA's review process for accelerated approval, including upcoming meetings to align on functional data and surrogate markers. He also touches on Solid's Friedreich's ataxia program and its potential to transform the treatment landscape.

Outlines

Part 1: Gene Therapy Approach, Clinical Data

Part 2: Cardiac Health, FDA Strategy

Part 3: Trial Design, Future Innovation

Part 4: Pipeline Expansion, Financial Outlook

Sign in to continue reading, translating and more.

Open full episode in Podwise

BiotechTV - News

Part 1: Gene Therapy Approach, Clinical Data

Solid Biosciences' Gene Therapy Approach for Muscular Dystrophy: Microdystrophin and Capsid Expertise

Solid Biosciences' Data Update: Safety, Microdystrophin Expression, and Durability in Duchenne Patients

Biomarkers and Muscle Stability: Predicting Functional Benefit in Duchenne Muscular Dystrophy

Part 2: Cardiac Health, FDA Strategy

Cardiac Benefits and Functional Data: Solid Biosciences' Approach to Duchenne Treatment

Aligning with the FDA: Solid Biosciences' Strategy for Accelerated Approval

Navigating FDA Meetings: A Strategic Approach to Accelerated Approval

Part 3: Trial Design, Future Innovation

FDA Relationship and Phase 3 Trial: Time to Rise as Primary Endpoint

Innovation and Combination Therapy: The Future of Duchenne Muscular Dystrophy Treatment

Part 4: Pipeline Expansion, Financial Outlook

Friedreich's Ataxia Program and Financial Runway: Solid Biosciences' Future

Solid Biosciences CEO Bo Cumo discusses recent DMD data for the company's microdystrophin gene therapy, and explains the development and regulatory steps ahead

BiotechTV - News

Part 1: Gene Therapy Approach, Clinical Data

00:13Solid Biosciences' Gene Therapy Approach for Muscular Dystrophy: Microdystrophin and Capsid Expertise

Solid Biosciences' Gene Therapy Approach for Muscular Dystrophy: Microdystrophin and Capsid Expertise

01:22Solid Biosciences' Data Update: Safety, Microdystrophin Expression, and Durability in Duchenne Patients

Solid Biosciences' Data Update: Safety, Microdystrophin Expression, and Durability in Duchenne Patients

04:55Biomarkers and Muscle Stability: Predicting Functional Benefit in Duchenne Muscular Dystrophy

Biomarkers and Muscle Stability: Predicting Functional Benefit in Duchenne Muscular Dystrophy

Part 2: Cardiac Health, FDA Strategy

07:17Cardiac Benefits and Functional Data: Solid Biosciences' Approach to Duchenne Treatment

Cardiac Benefits and Functional Data: Solid Biosciences' Approach to Duchenne Treatment

09:51Aligning with the FDA: Solid Biosciences' Strategy for Accelerated Approval

Aligning with the FDA: Solid Biosciences' Strategy for Accelerated Approval

11:31Navigating FDA Meetings: A Strategic Approach to Accelerated Approval

Navigating FDA Meetings: A Strategic Approach to Accelerated Approval

Part 3: Trial Design, Future Innovation

13:39FDA Relationship and Phase 3 Trial: Time to Rise as Primary Endpoint

FDA Relationship and Phase 3 Trial: Time to Rise as Primary Endpoint

16:42Innovation and Combination Therapy: The Future of Duchenne Muscular Dystrophy Treatment

Innovation and Combination Therapy: The Future of Duchenne Muscular Dystrophy Treatment

Part 4: Pipeline Expansion, Financial Outlook

19:01Friedreich's Ataxia Program and Financial Runway: Solid Biosciences' Future

Friedreich's Ataxia Program and Financial Runway: Solid Biosciences' Future